MFN changing the rules of the game for the Nordic countries

Recent GlobalData POLI analysis showed a 35% decline in pharmaceutical launches across Europe in the ten months after the ...

Regeneron wins gene therapy nod, signs MFN pact

The final major drugmaker President Donald Trump had pressed to accept a most-favored-nation deal has signed an agreement ...
The White House

Fact Sheet: President Donald J. Trump Announces Deal with Regeneron to Bring Most-Favored-Nation Pricing to American Patients

Today, President Donald J. Trump announced the 17th agreement with a major pharmaceutical manufacturer, Regeneron, to lower prescription drug prices that Americans pay for some of the world’s most ...
Fierce Pharma

Regeneron unveils latest 'most favored nation' drug pricing deal with White House

With Regeneron poised to announce a drug pricing deal with the White House Thursday, all 17 companies targeted in a round of ...
PharmExecOpinion

How Can Pharma Prices be Reduced for Americans Without Impacting Innovation?

While the goal is to reduce the cost burden on US patients, many in the industry are warning that there could be consequences ...
RealClearMarketsOpinion

The Importation of Failed European Drug Policies

Most Favored Nation (MFN) drug pricing is just price controls by another name. Instead of openly capping what a drug can cost ...
The Commonwealth FundOpinion

Beyond “Most Favored Nation” Drug Pricing: What the U.S. Can Learn from Other Countries

The renewed debate over Most Favored Nation (MFN) drug pricing in the United States reflects a legitimate frustration: ...
Pharm Exec

What Potential Fallout Will MFN Policies Have?

MFN policies are likely to impact more than pricing, and drug companies may alter drug launch plans in the future. With the launch of TrumpRx earlier this year, Americans got their first taste of how ...